

Curriculum Vitae

Melissa A.L. Vyfhuis, MD, PhD

Adjunct Associate Professor, Department of Radiation Oncology
University of Maryland Medical Center

Date January 26th, 2023

Contact Information

Business Address: **Department of Radiation Oncology**
305 Hospital Dr
Glen Burnie, MD 21061

Business Number: (410) 553-8369
Email: mvyfhuis@umm.edu
Foreign Languages: Spanish (Native)

Academic Appointments

2019-Present Visiting Adjunct Assistant Professor of Radiation Oncology
University of Maryland, Medical Center

2020-Present Chair of the Diversity and Inclusion Committee, Radiation
Oncology

Education

2001-2005 BS, Biochemistry and Molecular Biology, *cum laude*,
University of Maryland, Baltimore County

2007-2012 PhD, Biochemistry, University of Maryland, School of
Medicine
*Graduate Dissertation: Structure, Dynamics, and Function of
S100B and S100A5 complexes*
Thesis Advisor: Dr. David J. Weber

2005-2014 MD, University of Maryland, School of Medicine

Post Graduate Education and Training

- 2014-2015** Internship, University of Maryland Medical Center, Department of Internal Medicine
- 2015-2019** Residency, University of Maryland Medical Center, Department of Radiation Oncology
- 2021** Board Certified in Radiation Oncology

Medical Licensures

- 2019** Active, Maryland

Professional Society Memberships and Committees

- 2010 – Present** General Member, American Society for Radiation Oncology (ASTRO)
- 2019 – Present** ASTRO's Committee on Health Equity, Diversity and Inclusion (CHEDI)
- 2020 - Present** Chair of the Diversity and Inclusion Committee, University of Maryland Medical Center, Department of Radiation Oncology

Honors and Awards

- 2001 - 2005** Meyerhoff Undergraduate Scholarship, full scholarship including tuitions, room and board
- 2003 - 2005** MARC U* STAR (Minority Access to Research Careers Undergraduate Student Training in Undergraduate Research)
Undergraduate Scholarship
- 2002** ABRCMS (Annual Biomedical Research Conference for Minority Students) - First place in Biochemistry poster Session

- 2005** Medical Student Research Day - Second place, Poster Session: Point mutations in the HIV-1 matrix protein turn off the myristyl switch.
- 2007-2012** Meyerhoff Graduate Fellowship Award
- 2009** MARC (Minority Access to Research Careers) Travel Award to the ASBMB (American Society for Biochemistry and Molecular Biology) Annual Meeting at Experimental Biology
- 2009** Summer Research Fellowship in Radiation Oncology
- 2010** Keystone Symposium, Minority Scholarship recipient to attend meeting on Frontiers of NMR (Nuclear Magnetic Resonance) Biology
- 2011** ASTRO Minority Fellowship recipient
- 2013** Radiation Oncology Research Award
- 2017** ROI Excellence Award for the article “Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥ 60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer” published in Advances in Radiation Oncology
- 2017** Lynn Sage Symposium Scholar Award
- 2017-2018** Chief Resident, Department of Radiation Oncology
- 2018** Resident Manuscript of the Year Award for the article “Implications of Pathological Complete Response (pCR) at the Primary Tumor after Chemoradiotherapy (CRT) followed by Surgical Resection in Patients with Locally Advanced, Non-Small Cell Lung Cancer (LA-NSCLC)” published in the Red Journal

2018 H.E.R.O Nominee from the Radiation Oncology Department

2019 Mentor Recognition Award at the 42nd Annual Medical Student Research Day

Diversity, Equity and Inclusion Training/Initiatives

2020-Present Chair of the Diversity and Inclusion Committee, Radiation Oncology

- **Meet monthly with the DEI committee**, creating educational DEI-centric events for the Radiation Oncology Department
- Created an **Anonymous Feedback system** via Citrix so colleagues have a way to anonymously voice any DEI concerns in the department
- **DEI Book/Movie Club** – Started November 2021, quarterly event we host in the department discussing a diverse range of books and movies focusing on the voices of historically marginalized groups
- **DEI Speaker Series** – Once a year, we invite a speaker to discuss DEI themes:
 - o **May 2022:** Dr. Roderick King “*UMMS Equity, Diversity and Inclusion: Our Cultural Evolution*”
 - o **May 2023:** Dr. Karen Winkfield will be speaking on “Strategies in implementing Racial Equality in Radiation Oncology”

2022-Present **Moderator of the Allyship Program** (<https://leanin.org/allyship-at-work>)- training program that empowers employees to take meaningful action and build an inclusive workplace culture. We are teaching this program twice a year to the Radiation Oncology Department.

Teaching Service

Medical/Graduate Student Teaching

- 2017-present** Mentor, research advisor/PI, regular monthly meetings with students and residents
- 2021-present** Mentor in the ARRO Equity and Inclusion Subcommittee (EISC) Diversity Mentorship Program

Grant Support

- 2020 – 2023** \$30, 000 American Cancer Society Institutional Research Grant for the project Effects of Food Deserts on Cancer Care and Outcomes for two years. **Award number: ACS IRG-18-160-16**

Completed Grants:

- 2009-2012** Ruth L, Kirschstein National Research Service Award recipient (**F31**) – Grant Number 1F31CA144560 from the National Cancer Institute
Annual Direct Costs: \$50,000
Total Direct Costs: \$150,000

Clinical Protocols:

- **GCC 19134** – Principal Investigator – “Disparities and Breast Cancer Patients”
- **GCC-1939** - Principal Investigator – “Identifying Psychosocial, Demographic and Economic Variables Influencing Treatment Decisions and Outcomes in Oncological Care”
- **GCC 1175** – First Author/Co-Principal Investigator – “Thoracic oncology database” Retrospective review of stage III NSCLC patients focusing on patient demographic, treatment, toxicities and clinical outcomes in those treated with curative intent at our institution.

- **GCC 1875** – First Author/Co-Principal Investigator – “Preserving endocrine ovarian function in premenopausal women undergoing whole pelvis irradiation for cervical cancer): A dosimetric feasibility study comparing volumetric modulated arc therapy (VMAT) and intensity modulated proton therapy (IMPT)”

Publications:

Peer-reviewed journal articles

1. Saad JS, Loeliger E, Luncsford,P, **Liriano M**, Tai J, Kim A, Miller J, Joshi A, Freed EO, and Summers MF. Point mutations in the HIV-1 matrix protein turn off the myristyl switch. *Journal of Molecular Biology*. 2007 Feb; 366(2):574-85.
2. Wilder PT, Lin J, Bair CL, Charpentier TH, Yang D, **Liriano M**, Varney KM, Lee A, Oppenheim AB, Adhya S, Carrier F, Weber DJ. Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. *Biochim Biophys Acta*. 2006 Nov; 1763(11):1284-97.
3. Charpentier TH, Wilder PT, **Liriano MA**, Varney KM, Pozharski E, MacKerell AD Jr, Coop A, Toth EA, Weber DJ. Divalent metal ion complexes of S100B in the absence and presence of pentamidine. *J Mol Biol*. 2008 Sep; 382:56-73.
4. Charpentier TH, Wilder PT, **Liriano MA**, Varney KM, Zhong S, Coop A, Pozharski E, MacKerell AD Jr, Toth EA, Weber DJ. Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. *Biochemistry*. 2009 Jul; 48(26):6202-12.
5. Charpentier TH, Thompson LE, **Liriano MA**, Varney KM, Wilder PT, Pozharski E, Toth EA, Weber, DJ. The effects of the CapZ peptide (TRTK-12) binding to the S100B-Ca as examined by NMR and X-ray crystallography. *J Mol Biol*. 2010 Mar; 395(5): 1227-43.
6. Malashkevich V, Dulyaninova N, Ramagopal UA, **Liriano MA**, Varney K, Knight D, Brenowitz M, Weber D, Almo S, Bresnick, A. Phenothiazines inhibit S100A4 function by inducing protein oligomerization. *PNAS*. 2010 May; 107(19): 8605-10.
7. Wilder PT, Charpentier TH, **Liriano MA**, Gianni K, Varney KM, Pozharski E, Coop A, Toth EA, Mackerell AD, Weber DJ. In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction. *Int J High Throughput Screen*. 2010 Jul; 7(1): 109-126.

8. **Liriano MA**, Varney KM, Wright NT, Hoffman CL, Toth EA, Ishima R, Weber DJ. Target binding to S100B reduces its dynamic properties and increases Ca²⁺-binding affinity for wild type and EF-hand mutant proteins. *J Mol Biol.* 2012 Oct; 423(3): 365-85.
9. Hartman KG, McKnight LE, **Liriano MA**, Weber DJ. The evolution of S100B inhibitors for the treatment of malignant melanoma. *Future Med Chem.* 2013 Jan; 5(1): 97-109.
10. Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, **Vyfhuis M**, Scilla KA, Feigenberg SJ, Edelman MJ, Feliciano JL. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). *Lung Cancer.* 2017 Feb; 104: 52-57.
11. Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, **Vyfhuis MA**, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. *Oncologist.* 2017 Jun; 22(6): 737-742.
12. Diwanji T, Mohindra P, **Vyfhuis M**, Snider J, Kalavagunta C, Mossahebi S, Yu J, Feigenberg S, Badiyan S. Advances in radiotherapy techniques and delivery for NSCLC: Benefits of IMRT, proton therapy, and SBRT. *Transl Lung Cancer Res.* 2017 Apr;6(2):131-147
13. Remick J, Regine W, Malyapa R, Ng V, **Vyfhuis M**, Diwanji T, Shyu S, Snider JW. Excellent Pathologic Response and Atypical Clinical Course of High-Grade Extremity Sarcoma to Neoadjuvant Pencil Beam Scanning Proton Therapy. *Cureus.* 2017; 9(9): e1687
14. Schneider C, **Vyfhuis M**, Morse E, Diwanji T, Snider J, Mossahebi S, Steacy K, Malyapa R. Dramatic Response of a Large Sacral Chordoma to Intensity Modulated Proton Beam Therapy. *Cureus.* 2017; 9(9): e1670
15. Tsai A, **Vyfhuis M**, Francis M, Merechi F, Burke A, Regine W. Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Heart: A Case Report. *Practical Radiation Oncology.* 2018 Mar - Apr;8(2): 136-139
16. **Vyfhuis M**, Bhooshan N, Burrows W, Turner M, Suntharalingam M, Donahue J, Nichols E, Feliciano J, Bentzen S, Badiyan S, Carr S, Friedberg J, Simone II C, Edelman M, Feigenberg S, Mohindra P. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥ 60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. *Advances in Radiation Oncology.* 2017; 2(3):259-269
17. **Vyfhuis M**, Bhooshan N, Molitoris J, Bentzen S, Feliciano J, Edelman M, Burrows W, Nichols E, Suntharalingam M, Donahue J, Nagib M, Carr S, Friedberg J, Badiyan S, Simone II C, Feigenberg S, Mohindra P. Clinical

- outcomes of black vs. Non-black patients with locally advanced non-small cell lung cancer. *Lung Cancer*. 2017; 114:44-49
18. **Vyfhuis M**, Bhooshan N, Burrows W, Turner M, Suntharalingam M, Donahue J, Nichols E, Feliciano J, Bentzen S, Badiyan S, Carr S, Friedberg J, Simone II C, Edelman M, Feigenberg S, Mohindra P. Implications of Pathological Complete Response (pCR) at the Primary Tumor after Chemoradiotherapy (CRT) followed by Surgical Resection in Patients with Locally Advanced, Non-Small Cell Lung Cancer (LA-NSCLC). *International Journal of Radiation Oncology Biology Physics*. 2018; 101(2):445-452
 19. Rice S, Molitoris J, **Vyfhuis M**, Edelman M, Burrows M, Feliciano J, Nichols E, Suntharalingam M, Donahue J, Carr S, Friedberg J, Badiyan S, Simone 2nd C, Feigenberg S, Mohindra P. Nodal Size Predicts for Asymptomatic Brain Metastases in Non-Small Cell Lung Cancer Patients at Diagnosis. *Clinical Lung Cancer*. September 2018;pii:S1525-7304(18)30259-6.
 20. **Vyfhuis M**, Bentzen S, Bhooshan N, Edelman M, Burrows W, Nichols E, Suntharalingam M, Donahue J, Carr S, Friedberg J, Badiyan S, Simone II C, Feigenberg S, Mohindra P, Feliciano J. Marital status is an independent predictor of survival for stage III non-small cell lung cancer (NSCLC) patients undergoing definitive chemoradiation with or without surgery. *Journal of Community and Supportive Oncology*. September 2018;16(5);e194-e201.
 21. **Vyfhuis M**, Onyeuku N, Diwanji T, Mossahebi S, Badiyan S, Mohindra, P, Simone II C. Advances in proton therapy in lung cancer. 2018. *Therapeutic Advances in Respiratory Disease*. 2018; 12:1-16
 22. **Vyfhuis M**, Rice S, Remick J, Mossahebi S, Badiyan S, Mohindra P, Simone II C. Reirradiation for Locoregionally Recurrent Non-small cell lung cancer: A Review. *Journal of Thoracic Disease*. 2018; 10(21): S2522-S2536
 23. **Vyfhuis M**, Bentzen S, Molitoris J, Grover S, Badiyan S, Simone II C, Mohindra P. Patterns of Care and Survival in Black and Latino Patients as Compared to White Patients with Stage III Non-Small Cell Lung Cancer. *Clin Lung Cancer*. February 2019; pii: S1525-7304(19)30065-8.
 24. **Vyfhuis M**, Fellows Z, McGovern N, Mingyao Z, Mohindra P, Wong J, Nichols E. Preserving endocrine ovarian function in premenopausal women undergoing whole pelvis irradiation for cervical cancer: A dosimetric feasibility study. *Int J Particle Ther*. May 2019. 6(1): 10-17.
 25. **Vyfhuis M**, Mingyao Z, Agyepong B, Nichols E. Techniques for Treating Bilateral Breast Cancer Patients Using Pencil Beam Scanning Technology. *Int J Particle Ther*. September 2019. 6(2): 1-11.

26. Rice S, **Vyfhuis M**, Scilla K, Burrows W, Bhooshan N, Suntharalingam M, Edelman M, Feliciano J, Badiyan S, Simone 2nd C, Bentzen S, Feigenberg S, Mohindra P Insurance status is an independent predictor of overall survival in patients with stage III non-small cell lung cancer treated with curative intent. Clin Lung Cancer. August 2019. S1525-7304(19)30258-X.
27. Haskins CP, Champ CE, Miller Rm **Vyfhuis M**. Nutrition in Cancer: Evidence and Equality. Review, Advances in Radiation Oncology. 2020; 5, 817-823.
28. **Vyfhuis M**, Suzuki I, Bentzen S, Cullen K, Goloubeva O. Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis. Oncologist. 2021; 26(7):579-587.
29. Dahlia K, Savla B, Lievers A, Baker K, **Vyfhuis M**. Identifying Psychosocial Needs of Cancer Patients Undergoing Curative Radiation Therapy in an Inner-City Academic Center to Address Racial Disparities. International Journal of Radiation Oncology Biology Physics. Oct 2022; 114(2):185-194.
30. Kerans SJ, Samanta S, **Vyfhuis M**, Guerrero M, Bang C, Mishra M, Rana Z, Amin P, Kwok Y, Naslund M, Molitoris J. Identifying Racial Analysis of Clinical & Biochemical Outcomes in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics. 2022; 2022 Nov 38; Online ahead of print.
31. Savla B, Hamza M, Yacubovich D, Cobbs S, Petrovska L., Scilla K, Burrows W, Mehra R, Miller RC, Rolfo C, Bentzen SM, Mohindra P, **Vyfhuis M**. The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 2023; *Recently Accepted*;

Book Chapters

1. **Vyfhuis M** and Malyapa R. Chapter 5: Base of Skull Tumors: Chordoma and Chondrosarcoma Base of Skull. “Principles & Practice of Clinical Proton Therapy”

Abstracts and/or Proceedings

1. Markan U, Oswald P, Cheston SB, Mohindra P, Cobbs S, Nichols E, McAvoy S, **Vyfhuis M**. Factors that influence a woman's decision to enroll in breast cancer clinical trials – implications on how to improve minority enrollment and retention (poster). ASTRO Meeting, October 2022.
2. Savla B, Hamza M, Markan K, Yacubovich D, Cobbs S, Petrovska L, Scilla K, Burrows W, Mehra R, Miller RC, Rolfo C, Mohindra P, **Vyfhuis M**. The Impact of Body Mass Index and Residence in Food Priority Areas on Patterns-of-Care and Cancer Outcomes in Patients with Stage III Non-Small Cell Lung Cancer (poster). ASTRO Meeting, October 2022.
3. Cohen JD, Sanchez-Cerro MK, **Vyfhuis M**, Patel AN, Dudley SA, Mohindra P. Role of Modified Frailty Index in Predicting Oncologic Outcomes From Moderately Hypofractionated Radiotherapy for Patients with Stage I-II B Non-Small Cell Lung Cancer (poster). ASTRO Meeting, October 2021.
4. Markan K, Saeed A, Hamza MA, **Vyfhuis M**, Rolfo C, Mohindra P. Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy (poster). ASTRO Meeting, October 2021.
5. Nichols EM, Decesaris C, Paulosky K, Yacubovich D, McAvoy SA, **Vyfhuis M**. Cardiac Risk Factors in Black Women With Breast Cancer Undergoing Proton Therapy (PBT): Potential for Increased Therapeutic Gain (poster). ASTRO Meeting, October 2021.
6. Savla B, Hamza M, Markan K, Yacubovich D, Cobbs S, Scilla K, Burrows W, Mehra R, Miller RC, Rolfo C, Mohindra P, **Vyfhuis M**. Residing in Food Priority Areas (FPAs) Correlates with Unique Socioeconomic Demographics and Patterns-of-care in Patients with Stage III Non-small Cell Lung Cancer (NSCLC) (poster). Virtual ARS Meeting, September 2021. **Awarded one of the Best Poster at the Conference.**
7. Markan U, Decesaris C, Oswald P, Cheston S, Mohindra P, Nichols E, McAvoy S, **Vyfhuis M**. Factors that influence a woman's decision to enroll in breast cancer clinical trials – implications on how to improve minority enrollment and retention. **(Oral)**. ACRO Meeting, February 2021. **Awarded the Bronze Metal at the Conference.**
8. Saeed AM, **Vyfhuis M**, Scilla KA, Molitoris JK Simone CB II, Burrows WM, Mehra R, Rolfo C, Miller RC, Mohindra P. Clinical

- Outcomes in Non-Small Cell Lung Cancer Patients Treated with Pencil Beam Scanning Proton Reirradiation after Previous Thoracic Radiation. (poster). Virtual ASTRO Meeting, October 2020.
9. Hamza, M, Mohindra, P, Bentzen S, Schilla K, Burrows W, Mehra R, Rolfo C, Miller R, **Vyfhuis M**. Effects of living in food priority areas on treatment and outcomes in patients with stage III NSCLC. (poster). Virtual ASTRO Meeting, October 2020.
 10. Haskins C, Kronfli D, Lievers A, **Haskins CP**, Kronfli D, **Lievers A**, Waldo L, Baker K, Bentzen S, Mohindra P, **Vyfhuis M**. Characterizing definitively treated cancer patients living within food priority areas (FPAs) to find predictors of perceived access to healthy meals (poster). Virtual ASTRO Meeting, October 2020.
 11. **Vyfhuis M**, Bentzen S, Feliciano J, Simone II C, Mohindra P. Survival and Patterns of Care Comparing Black and White Patients with All Stages of NSCLC: An NCDB Analysis. (poster) WLC Meeting in Toronto, September 2018.
 12. **Vyfhuis M**, Bhooshan N, Molitoris J, Bentzen S, Feliciano J, Edelman M, Burrows W, Nichols E, Suntharalingam M, Donahue J, Nagib M, Carr S, Friedberg J, Badiyan S, Simone II C, Feigenberg S, Mohindra P. Black patients with locally advanced non-small cell lung cancer (LA-NSCLC) - An inclusive multi-modality approach is justified. (poster) American Radium Society (ARS) Annual Meeting meeting in Colorado Springs, May 2017.
 13. **Vyfhuis M**, Bhooshan N, Bentzen S, Nichols EM, Burrows W, Battafarano R, Bodor M, Edelman M, Feliciano J, Feigenberg SJ, Mohindra P. Clinical predictors of complete pathologic response in patients considered for trimodality treatment with locally advanced, stage III NSCLC. (poster) ASTRO Meeting in Boston, September 2016.
 14. Rice S, Molitoris JK, **Vyfhuis M**, Mohindra P, Feliciano J, Badiyan SN, Nichols EM, Edelman MJ, Friedberg J, Burrows WM, Feigenberg SJ. Magnetic resonance imaging brain staging in stage I-III non-small cell lung cancer (NSCLC): Incidence and clinicopathologic factors in asymptomatic brain metastases at diagnosis. (poster) ASTRO Meeting in Boston, September 2016.
 15. Bhooshan N, **Vyfhuis M**, Feliciano J, Bentzen SM, Nichols EM, Edelman MJ, Burrows W, Suntharalingam M, Carr S, Friedberg J, Badiyan SN, Feigenberg SJ, Mohindra P. Patterns of Recurrence in Patients with Locally Advanced Non-Small Cell Lung Cancer (LANSCCLC) Treated With Concurrent Chemoradiation (CRT) Followed by Surgery. (poster) ASTRO Meeting in Boston, September 2016.

- 16.**Hyder J, Bhooshan N, Feliciano J, **Vyfhuis M**, Lam V, Suntharalingam M, Burrows W, Nichols E, Edelman MJ, Feigenberg S, Cohen EP, Vujaskovic Z, Mohindra P. Pathological Response with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker use in Advanced Non-small cell Lung Cancer. (poster) IASLC Meeting in Denver, September 2015.
- 17.**Schrenk KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, **Vyfhuis M**, Bhooshan N, Feigenberg SJ, Edelman M, Feliciano JL. Neutrophil-Lymphocyte Ratio (NLR) as a Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer (LANSCLC). (poster) IASLC Meeting in Denver, September 2015.
- 18.**Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, **Vyfhuis M**, Feigenberg SJ, Edelman M, Feliciano JL. Obesity Is Associated with Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). (poster) IASLC Meeting in Denver, September 2015.
- 19.**Feliciano JL, Bentzen SM, Lam VK, Schrenk KA, Mohindra P, Nichols EM, **Vyfhuis M**, Bhooshan N, Feigenberg SJ, Edelman M. Marital Status Is Strongly Prognostic and Associated with More Favorable Nutritional Status in Locally Advanced Non-Small Cell Lung Cancer. (poster) IASLC Meeting in Denver, September 2015.
- 20.****Liriano, M.** Nichols E, Morris CG, Burrows W, Battafarano RJ, Garofalo MC, Turner M, Suntharalingam M, Edelman MJ, Feigenberg, SJ. Trimodality therapy for locally advanced non-small cell lung cancer (NSCLC). Tenth Annual Medical Students' Steps to Success meeting at the Uniformed Services University in Bethesda, Maryland, April 2013.
- 21.****Liriano, M.** Nichols E, Morris CG, Burrows W, Battafarano RJ, Garofalo MC, Turner M, Suntharalingam M, Edelman MJ, Feigenberg, SJ. Trimodality therapy for locally advanced non-small cell lung cancer (NSCLC). Thoracic Symposium Meeting in Chicago, Illinois, August 2012.
- 22.****Liriano, M.** and Weber, D. Protein dynamics of S100B and ^{D63N}S100B in the presence and absence of a CapZ-derived peptide (TRTK-12). SACNAS (Society for Advancement of Chicanos and Native Americans in Science) Meeting in San Jose, California, October 2011.
- 23.****Liriano, M.** and Weber, D. ¹⁵N-backbone and side-chain dynamics of the mutant calcium-binding protein S100B D63N. AACR (American Association for Cancer Research) Meeting in Orlando, Florida, April 2011.
- 24.****Liriano, M.** and Weber, D. Relaxation dispersion profiles of the calcium-

- binding proteins S100A5 and S100A1. *Frontiers in NMR Biology Meeting in Big Sky, Montana, January 2011.*
- 25. Liriano, M.** and Weber, D. Relaxation dispersion profiles of the calcium-binding proteins S100A5 and S100A1. *Protein Society Meeting in San Diego, California, August 2010.*
 - 26. Liriano, M.** and Weber, D. Protein dynamics of S100A5 and S100B D63N in the presence and absence of target peptide. *First Annual Cancer Biology Retreat in Baltimore, Maryland, March 2010.*
 - 27. Liriano, M.** and Weber, D. Protein dynamics of the calcium-binding protein S100A5 in the presence and absence of target. *MD/PhD First Annual Conference in Baltimore, Maryland, July 2009.*
 - 28. Liriano, M.** and Weber, D. Protein dynamics of the calcium-binding protein S100A5 in the presence and absence of target. *MD/PhD Annual Conference in Keystone, Colorado, July 2009.*
 - 29. Liriano, M.** and Weber, D. Protein dynamics of the calcium-binding protein S100A5 in the presence and absence of target. *ASBMB (Annual Biomedical Research Conference for Minority Students) Meeting at Experimental Biology in New Orleans, Louisiana, April 2009.*
 - 30. Liriano, M.** and Weber, D. Structure activity relationships of small molecules interfering with the S100B and p53 interaction. *Graduate Research Symposium at the University of Maryland, School of Medicine, Baltimore, Maryland, March 2008.*
 - 31. Liriano, M.** and Summers, M. Point mutations in the HIV-1 matrix protein turn off the myristyl switch. *Medical Student Research Day at the University of Maryland, School of Medicine, Baltimore, Maryland, October 2005.*
 - 32. Liriano, M.** and Summers, M. Structure elucidation of mutated matrix portion of HIV-1 protein. *ABRCMS (Annual Biomedical Research Conference for Minority Students), Dallas, Texas, November 2004.*
 - 33. Liriano, M.** and Caragine, T. DNA identification of irradiated evidence. *ABRCMS (Annual Biomedical Research Conference for Minority Students), San Diego, California, November 2003.*
 - 34. Liriano, M.** and Lima, C. Structural and functional characteristics of evolutionary conserved large G-proteins. *ABRCMS (Annual Biomedical Research Conference for Minority Students), New Orleans, Louisiana, November 2002.*

Other Brief communications

1. **Vyfhuis M**, Lassman A, Mehta M. Does WBRT still have a role for limited brain metastases? Point/Counter. *HemeOnc Today*. 2018; 19(3):11
2. **Vyfhuis M**, Lassman A, Mehta M. Radiation choice for brain metastases requires transparent discussion of tradeoffs. Commentary. *HemeOnc Today*. 2018; 19(4):1-9
3. **Vyfhuis M** and Edelman M. The Role for Trimodality Therapy in Stage III NSCLC. Commentary. *LungCancerNews*. 2018;
4. **Vyfhuis M**, Mohindra, P, Simone II C. Stereotactic Body Radiation Therapy versus Thermal Ablation for Early Stage Non-small Cell Lung Cancer. Letter-to-the-editor, *Radiology*. 2019; 290(2):574-575.
5. **Vyfhuis M**, Mohindra, P, Simone II C. Surgery for Early-stage Small Cell Lung Cancer: Is it worth it? Editorial Commentary, *Mediastinum*. 2019; *In press*.

Major Invited Speeches

Local

1. **Vyfhuis, M.** “The Management of Lung Cancer Review”, Department of Radiation Oncology at UMMC, 2016
2. **Vyfhuis, M.** “Pediatric Review: Management of Ewings Sarcoma”, Department of Radiation Oncology at UMMC, 2017
3. **Vyfhuis, M.** “Genitourinary Review”, Department of Radiation Oncology at UMMC, 2017
4. **Vyfhuis, M.** “The management of Cervical and Endometrial Cancer Review”, Department of Radiation Oncology at UMMC, 2018
5. **Vyfhuis, M.** “The glass ceiling of locally advanced NSCLC: addressing locoregional control and disparities”, Department of Radiation Oncology at Georgetown, 2018
6. **Vyfhuis, M.** “The glass ceiling of locally advanced NSCLC: addressing locoregional control and disparities”, Department of Radiation Oncology at JHH, February 2019
7. **Vyfhuis, M.** “The glass ceiling of locally advanced NSCLC: addressing locoregional control and disparities”, Department of Radiation Oncology at University of Miami, Grand Rounds, 2019

National

1. **Liriano, M.** and Weber, D. “Structure activity relationships of small molecules interfering with the S100B and p53 interaction”, Meyerhoff 20th Anniversary Symposium, Baltimore, MD, 2008.

2. **Liriano, M.** Nichols E, Morris CG, Burrows W, Battafarano RJ, Garofalo MC, Turner M, Suntharalingam M, Edelman MJ, Feigenberg, SJ. “Trimodality therapy for locally advanced non-small cell lung cancer (NSCLC).” ASTRO Meeting in Boston, Massachusetts, October 2012.
3. Bhooshan N, Edelman MJ, Nichols E, **Vyfhuis M**, Feliciano J, Burrows W, Suntharalingam M, D’Souza W, Vujaskovic Z, Feigenberg S, Mohindra P. “Does Severe Radiation Pneumonitis (RP) Affect Clinical Outcomes in Non-Operable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Carboplatin/Paclitaxel (CP)-based Concurrent Chemoradiation Therapy (CRT)?”, ASTRO Meeting in San Antonio, October 2015.
4. Rice S, **Vyfhuis M**, Bhooshan N, Edelman MJ, Burrows W, Nichols EM, Suntharalingam M, Donahue J, Carr S, Friedberg J, Badiyan SN, Feliciano J, Feigenberg SJ, Mohindra P. “Does insurance status impact survival outcomes in patients with stage III NSCLC treated with curative intent?” American Radium Society (ARS) Annual meeting in Colorado Springs, May 2017.
5. **Vyfhuis M**, Bhooshan N, Molitoris J, Bentzen S, Feliciano J, Edelman M, Burrows W, Nichols E, Suntharalingam M, Donahue J, Nagib M, Carr S, Friedberg J, Badiyan S, Simone II C, Feigenberg S, Mohindra P. Black patients with locally advanced non-small cell lung cancer (LA-NSCLC) “An inclusive multi-modality approach is justified.” ASTRO Meeting in San Diego, September 2017.
6. Markan U, Decesaris C, Oswald, P, Cheston S, Mohindra P, Nichols E, McAvoy S, **Vyfhuis M**. “Factors that influence a woman’s decision to enroll in breast cancer clinical trials – implications on how to improve minority enrollment and retention” ACRO Meeting Virtual, February 2021. *Bronze medal winner.*